BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 16963144)

  • 21. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
    Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
    Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
    J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
    Arai T; Benny O; Joki T; Menon LG; Machluf M; Abe T; Carroll RS; Black PM
    Anticancer Res; 2010 Apr; 30(4):1057-64. PubMed ID: 20530409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
    Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [PEG-liposome in DDS and clinical studies].
    Maruyama K
    Nihon Rinsho; 1998 Mar; 56(3):632-7. PubMed ID: 9549348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
    Cheng WW; Allen TM
    J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals.
    Qin Y; Chen H; Zhang Q; Wang X; Yuan W; Kuai R; Tang J; Zhang L; Zhang Z; Zhang Q; Liu J; He Q
    Int J Pharm; 2011 Nov; 420(2):304-12. PubMed ID: 21945185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Basic studies on chemotherapy of brain tumors by means of liposomes: affinity of sulfatide-inserted liposomes to human glioma cells].
    Kito A; Yoshida J; Kageyama N; Inoue I; Abe H; Arichi S; Kojima N; Yagi K
    No To Shinkei; 1987 Aug; 39(8):783-8. PubMed ID: 3426863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
    Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
    J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted delivery via avidin fusion protein: intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes.
    Soininen SK; Lehtolainen-Dalkilic P; Karppinen T; Puustinen T; Dragneva G; Kaikkonen MU; Jauhiainen M; Allart B; Selwood DL; Wirth T; Lesch HP; Määttä AM; Mönkkönen J; Ylä-Herttuala S; Ruponen M
    Eur J Pharm Sci; 2012 Dec; 47(5):848-56. PubMed ID: 22985874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals.
    Ying X; Wen H; Lu WL; Du J; Guo J; Tian W; Men Y; Zhang Y; Li RJ; Yang TY; Shang DW; Lou JN; Zhang LR; Zhang Q
    J Control Release; 2010 Jan; 141(2):183-92. PubMed ID: 19799948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
    Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
    J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
    He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
    Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy.
    Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R
    J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disaccharide-modified liposomes and their in vitro intracellular uptake.
    Song CK; Jung SH; Kim DD; Jeong KS; Shin BC; Seong H
    Int J Pharm; 2009 Oct; 380(1-2):161-9. PubMed ID: 19635539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of adriamycin entrapped by sulfatide-containing liposomes on ovarian tumor-bearing nude mice.
    Kojima N; Ueno N; Takano M; Yabushita H; Noguchi M; Ishihara M; Yagi K
    Biotechnol Appl Biochem; 1986 Oct; 8(5):471-8. PubMed ID: 3768148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
    J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.